Pyridone and aza-pyridone compounds and methods of use
Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
1. A compound selected from Formula I:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein:
R 1 is H, D, F, Cl, CN, —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OH, —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 OH, heteroaryl selected from imidazolyl and pyrazolyl, heterocyclyl selected from oxetanyl and azetidinyl, and C 1 -C 3 alkyl;
R 2 , R 3 and R 4 are independently selected from H, D, F, Cl, —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OH, —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 OH, and C 1 -C 3 alkyl;
R 5 is optionally substituted C 6 -C 20 aryl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, —(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), —(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), —(C 1 -C 20 heteroaryl)-(C 1 -C 6 alkyl), or —(C 1 -C 20 heteroaryl)-C(═O)—(C 2 -C 20 heterocyclyl);
R 6 is H, F, —NH 2 , —OH, or optionally substituted C 1 -C 3 alkyl;
X is S, S(═O), S(═O) 2 , N, NR 6 , O, or CR 7 ;
R 7 is independently selected from H, D, F, Cl, —CH 3 , —CH 2 CH 3 , —CN, —CH 2 F, —CHF 2 , —CF 3 , —NH 2 , —OH, and —OCH 3 ;
Y 1 and Y 2 are independently selected from CR 6 and N;
Z 1 , Z 2 , Z 3 , and Z 4 are independently selected from C, CR 7 , and N;
Z 5 is —CR 3 ═N—;
one of Z 1 and Z 2 , or X and Z 1 , where X is not S, S(═O), or S(═O) 2 , forms a five-, six-, or seven-membered aryl, carbocyclyl, heterocyclyl or heteroaryl ring;
where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from D, F, Cl, Br, I, —CH 3 , —CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 OH, —CH 2 CH 2 OH, —C(CH 3 ) 2 OH, —CH(OH)CH(CH 3 ) 2 , —C(CH 3 ) 2 CH 2 OH, —CH 2 CH 2 SO 2 CH 3 , —CH 2 OP(O)(OH) 2 , —CN, —CH 2 F, —CHF 2 , —CF 3 , —CO 2 H, —COCH 3 , —CO 2 CH 3 , —CO 2 C(CH 3 ) 3 , —COCH(OH)CH 3 , —CONH 2 , —CONHCH 3 , —CON(CH 3 ) 2 , —C(CH 3 ) 2 CONH 2 , —NO 2 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHCOCH 3 , —N(CH 3 )COCH 3 , —NHS(O) 2 CH 3 , —N(CH 3 )C(CH 3 ) 2 CONH 2 , —N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , ═O, —OH, —OCH 3 , —OCH 2 CH 2 N(CH 3 ) 2 , —OP(O)(OH) 2 , —S(O) 2 N(CH 3 ) 2 , —SCH 3 , —CH 2 OCH 3 , —S(O) 2 CH 3 , cyclopropyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, oxetanyl, and morpholino.
2. The compound of claim 1 selected from Formulas Ia-c:
3. The compound of claim 1 selected from Formulas Id-f:
4. The compound of claim 1 selected from Formulas Ig-n:
5. The compound of claim 1 selected from Formulas Io-t:
6. The compound of claim 1 where Z 1 and Z 2 forms a five-, six-, or seven-membered aryl, carbocyclyl, heterocyclyl or heteroaryl ring, and selected from Formulas Iaa-ap:
7. The compound of claim 1 where X and Z 1 , and X is not S, forms a five-, six-, or seven-membered aryl, carbocyclyl, heterocyclyl or heteroaryl ring, and selected from Formulas Iaq-bf:
8. The compound of claim 1 where the group:
forms the structures:
where the wavy line indicates the site of attachment.
9. The compound of claim 1 wherein R 1 , R 2 , R 3 , and R 4 are each H.
10. The compound of claim 1 wherein R 1 is selected from F, —CH 3 , —CH 2 F, —CHF 2 , and —CF 3 .
11. The compound of claim 1 wherein R 1 is —CH 2 OH.
12. The compound of claim 1 wherein R 3 is F.
13. The compound of claim 1 wherein R 1 is —CH 2 OH, R 2 and R 4 are each H, and R 3 is F.
14. The compound of claim 1 wherein R 5 is optionally substituted C 6 -C 20 aryl selected from phenyl and naphthyl.
15. The compound of claim 1 wherein R 5 is optionally substituted C 3 -C 12 carbocyclyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
16. The compound of claim 1 wherein R 5 is optionally substituted C 2 -C 20 heterocyclyl selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, and tetrahydropyranyl.
17. The compound of claim 1 wherein R 5 is optionally substituted C 1 -C 20 heteroaryl selected from pyrazolyl, pyridinyl, pyrimidinyl, 5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl, 5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl, and 1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-yl.
18. The compound of claim 17 wherein R 5 is substituted with one or more groups selected from F, Cl, —CH 3 , cyclopropyl, azetidinyl, oxetanyl, and morpholino.
19. The compound of claim 1 wherein R 5 is selected from the structures:
where the wavy line indicates the site of attachment.
20. The compound of claim 1 wherein R 6 is H.
21. The compound of claim 1 wherein X is S.
22. The compound of claim 1 wherein X is N.
23. The compound of claim 1 wherein X is CR 7 .
24. The compound of claim 1 wherein Y 1 is CR 6 and Y 2 is N.
25. The compound of claim 1 wherein Y 1 is N and Y 2 is CR 6 .
26. The compound of claim 1 wherein Y 1 and Y 2 are each CR 6 .
27. The compound of claim 1 selected from:
5-[5-fluoro-2-(hydroxymethyl)-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]phenyl]-8-thia-4,5-diazatricyclo[7.4.0.0 2,7 ]-trideca-1(9),2(7),3(4)-trien-6-one,
5-[5-fluoro-2-(hydroxymethyl)-3-[1-methyl-5-({5-[4-methylpiperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]phenyl]-8-thia-4,5-diazatricyclo[7.4.0.0 2,7 ]-trideca-1(9),2(7),3(4)-trien-6-one,
3-(5-Fluoro-2-hydroxymethyl-3-{1-methyl-5-[6-(4-methyl-piperazin-1-yl)-pyridazin-3-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one,
3-(5-Fluoro-2-hydroxymethyl-3-{1-methyl-5-[6-(4-oxetan-3-yl-piperazin-1-yl)-pyridazin-3-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one,
2-(5-fluoro-2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-6,7,8,9-tetrahydro-[1,2,4]triazino[4,5-a]indol-1(2H)-one, and
2-(5-fluoro-2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-6,7,8,9-tetrahydro-[1,2,4]triazino[4,5-a]indol-1(2H)-one.
28. A pharmaceutical composition comprised of a compound of claim 1 and a pharmaceutically acceptable carrier, glidant, diluent, or excipient.
29. The pharmaceutical composition of to claim 28 , further comprising a second therapeutic agent.
30. A process for making a pharmaceutical composition which comprises combining a compound of claim 1 with a pharmaceutically acceptable carrier.